Vascular Biogenics Ltd.

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

NASDAQ:VBLT

Vascular Biogenics Ltd.

Last Close

0.17

16/10 20:00

Market Cap

12.11M

Beta: 0.68

Volume Today

5.38M

Avg: 4.45M

PE Ratio

−0.97

PFCF: −0.69

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics